Form 4: T2 Biosystems General Counsel Acquires Shares Through RSU Vesting

Michael Terrence Gibbs, General Counsel of T2 Biosystems, acquired 29 shares of common stock on February 24, 2024, through the vesting of restricted stock units.

Summary

• On February 24, 2024, Michael Terrence Gibbs, the General Counsel of T2 Biosystems, acquired 29 shares of common stock.
• This acquisition resulted from the vesting of restricted stock units (RSUs).
• The RSUs were initially granted on February 24, 2021, and vest in three equal annual installments starting February 24, 2022.
• Each RSU represents the right to receive one share of T2 Biosystems common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The vesting of RSUs indicates a continued alignment of the General Counsel's interests with those of the company and its shareholders.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the vesting of previously granted equity compensation.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it involves the vesting of previously granted equity compensation.

Key Dates

Keywords

T2 Biosystems, Gibbs, Michael Terrence Gibbs, RSU, Restricted Stock Units, Form 4, Beneficial Ownership, General Counsel, TTOO